Praxis Precision Medicines Financial Ratios
NASDAQ: PRAXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
259.86-3.69 (-1.40%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Praxis Precision Medicines ratio analysis
Return on equity reached -34.5%, meaning Praxis Precision Medicines generated -0.35 dollars of profit for every dollar of shareholders' equity. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Praxis Precision Medicines financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Price / sales | — | 169.44 | 60.04 | — | — | — | — |
| Price / book | 7.34 | 3.25 | 2.11 | 1.44 | 50.02 | 25.70 | — |
| Operating margin | — | -2,340.3% | -5,164.4% | — | — | — | — |
| Net margin | — | -2,137.5% | -5,037.9% | — | — | — | — |
| Free cash flow margin | — | -1,540.5% | -4,543.8% | — | — | — | — |
| Return on equity (ROE) | -34.5% | -41.0% | -176.9% | -281.2% | -66.6% | -21.5% | — |
| Return on assets (ROA) | -32.3% | -37.8% | -140.2% | -185.9% | -57.1% | -20.4% | -74.5% |
| Current ratio | 10.22 | 10.77 | 5.39 | 3.23 | 7.48 | 19.23 | 6.67 |
| Revenue growth | -100.0% | 249.5% | — | — | — | — | — |